|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accounts receivables, net of allowance for credit losses of $75 million and $81 million as of June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Prepaid expenses | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Assets held for sale | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Deferred income taxes | ||||||||||||||||||||
| Other non-current assets | ||||||||||||||||||||
| Property, plant and equipment, net | ||||||||||||||||||||
| Operating lease right-of-use assets, net | ||||||||||||||||||||
| Identifiable intangible assets, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND EQUITY | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Short-term debt | ||||||||||||||||||||
| Sales reserves and allowances | ||||||||||||||||||||
| Accounts payables | ||||||||||||||||||||
| Employee-related obligations | ||||||||||||||||||||
| Accrued expenses | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| Liabilities held for sale | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Long-term liabilities: | ||||||||||||||||||||
| Deferred income taxes | ||||||||||||||||||||
| Other taxes and long-term liabilities | ||||||||||||||||||||
| Senior notes and loans | ||||||||||||||||||||
| Operating lease liabilities | ||||||||||||||||||||
| Total long-term liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Redeemable non-controlling interests | ||||||||||||||||||||
| Teva shareholders' equity: | ||||||||||||||||||||
| Ordinary shares of NIS 0.10 par value per share; June 30, 2026 and December 31, 2025: authorized 2,495 million shares; issued 1,271 million shares and 1,257 million shares, respectively. | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Treasury shares as of June 30, 2026 and December 31, 2025: 106 million ordinary shares and 107 million ordinary shares, respectively | ||||||||||||||||||||
| Stockholders' equity attributable to Teva shareholders | ||||||||||||||||||||
| Non-controlling interests | ||||||||||||||||||||
| Total equity | ||||||||||||||||||||
| Total liabilities and equity |
Loading...
